Jun.5,2003  48  US 2003/0104041 Al  56.  The system of claim 55 wherein the polymeric adhe› sive serves as the means for maintaining the system in agent  and base transmitting relationship to the body service.  57.  The system of claim 53 wherein the drug reservoir is  comprised of a hydrogel.  58.  The system of claim 53 wherein the drug reservoir is  comprised of a sealed pouch containing the analgesic agent  and inorganic base in a liquid or semi-solid formulation.  59.  The system of claim 53 wherein the analgesic agent is  an acidic species.  60.  The system of claim 59 wherein the base is present in  an amount that is the total of ( a) the amount required to  neutralize the acidic species plus (b) an amount equal to  about 0.3-7 .0 wt  %  of the drug reservoir.  61.  The system of claim 53 wherein the analgesic agent is  a non-acidic species.  62.  The system of claim 61 wherein the base is present in  an amount equal to about 0.3-7 .0 wt  %  of the drug reservoir.  63.  The system of claim 53 wherein the composition  provides for at least about 6-fold enhanced delivery.  64.  The system of claim 53 wherein the base is selected  from the group consisting of inorganic hydroxides, inorganic  oxides, inorganic salts of weak acids, and combinations  thereof.  65.  The system of claim 64 wherein the base is an  inorganic hydroxide selected from the group consisting of  ammonium  hydroxide,  sodium  hydroxide,  potassium  hydroxide, calcium hydroxide and magnesium hydroxide.  66.  The system of claim 64 wherein the base is an  inorganic oxide selected from the group consisting of mag› nesium oxide and calcium oxide.  67.  The system of claim 64 wherein the base is an  inorganic salt of a weak acid selected from the group  consisting of ammonium phosphate, sodium acetate, sodium  borate, sodium metaborate, sodium carbonate, sodium bicar› bonate, sodium phosphate, potassium carbonate, potassium  bicarbonate, potassium citrate, potassium acetate, and potas› sium phosphate.  68.  The system of claim 53 wherein the analgesic agent is  selected from the group consisting of capsaicin, clonidine,  tramadol,  indomethacin,  pharmaceutically  acceptable  derivatives thereof, and combinations thereof.  69.  The system of claim 53 wherein the analgesic drug is  a narcotic analgesic.  70.  The system of claim 69 wherein the analgesic agent is  selected from the group consisting of alfentanil, buprenor› phine, butorphanol, codeine, enkephalin, fentanyl, hydroc› odone, hydromorphone, levorphanol, meperidine, metha› done,  morphine,  nicomorphine,  opium,  oxycodone,  oxymorphone, pentazocine, propoxyphene, sufentanil, phar› maceutically acceptable derivatives thereof, and combina› tions thereof.  71.  The system of claim  70  wherein the analgesic agent is  selected from the group consisting of buprenorphine, butor› phanol, fentanyl, hydrocodone, hydromorphone, levorpha› nol, methadone, morphine, oxycodone, oxymorphone, phar› maceutically  acceptable  derivatives  thereof,  and  combinations thereof.  72.  The system of claim 53 which further comprises at  least one irritation-mitigating additive.  * * * * * 